AI assistant
INVION LIMITED — Major Shareholding Notification 2021
Dec 15, 2021
65148_rns_2021-12-15_43642ec1-5f0b-486c-9ecc-bd21566522f9.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
ASX Announcement 16 December 2021
==> picture [146 x 53] intentionally omitted <==
Top 20 Listed Option Holders
Invion Limited (ASX:IVX) (“Invion” or the “Company”) advises that a current statement setting out the names of the top 20 largest listed option holders and the percentage held by each is below.
| below. | |||
|---|---|---|---|
| Rank | Name | Current Balance |
% Listed Options |
| 1 | CS THIRD NOMINEES PTY LIMITED | 28,977,273 | 10.17% |
| 2 | CS FOURTH NOMINEES PTY LIMITED | 23,364,306 | 8.20% |
| 3 | MS CHUNYAN NIU | 20,727,851 | 7.27% |
| 4 | 180 MARKETS PTY LTD | 15,000,000 | 5.26% |
| 5 | EVOLUTION CAPITAL PTY LTD | 15,000,000 | 5.26% |
| 6 | MR BIN LIU | 11,582,415 | 4.06% |
| 7 | SPICEME CAPITAL PTY LTD | 10,750,000 | 3.77% |
| 8 | MR MATTHEW QI | 5,644,352 | 1.98% |
| 9 | ORCA CAPITAL GMBH | 5,625,000 | 1.97% |
| 10 | MATTHEW BURFORD SUPER FUND PTY LTD | 5,618,529 | 1.97% |
| 11 | DRH SUPERANNUATION PTY LTD | 5,113,637 | 1.79% |
| 12 | MORSEC NOMINEES PTY LTD | 4,745,686 | 1.67% |
| 13 | HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED – A/C 2 | 4,261,364 | 1.50% |
| 14 | ABN AMRO CLEARING SYDNEY NOMINEES PTY LTD | 3,977,273 | 1.40% |
| 15 | HUNTER CAPITAL ADVISORS P/L | 3,750,000 | 1.32% |
| 16 | MR DANIEL MORRIS KENNEDY | 3,750,000 | 1.32% |
| 17 | MISHTALEM PTY LTD | 3,750,000 | 1.32% |
| 18 | MR RICKY STEVEN NEUMANN | 3,750,000 | 1.32% |
| 19 | FIRST OAK CAPITAL PTY LTD | 3,409,091 | 1.20% |
| 20 | HIRSCH FINANCIAL PTY LTD | 3,409,091 | 1.20% |
| Total 182,205,868 | |||
| Grand Total 284,981,422 |
--ENDS--
This announcement is authorised for release to the market by the Company Secretary of Invion Limited.
Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 3 9692 7222 W: www.inviongroup.com
==> picture [146 x 53] intentionally omitted <==
Investor and Media enquiries:
Thian Chew (Chairman) Brendon Lau (Investor & Media Relations) T: +61 3 9692 7222 T: +61 409 341 613 E: [email protected] E: [email protected]
About Invion
Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact [email protected].
About Photodynamic Therapy (PDT)
Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.
Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 3 9692 7222 W: www.inviongroup.com